A Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 25 Sep 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Docetaxel (Primary) ; Elraglusib (Primary) ; Gemcitabine (Primary)
Indications Ewing's sarcoma; Fibroma; Haemangiosarcoma; Leiomyosarcoma; Malignant fibrous histiocytoma; Osteosarcoma; Rhabdomyosarcoma; Sarcoma; Soft tissue sarcoma; Synovial sarcoma
Focus Therapeutic Use

26 Jul 2021 Status changed from not yet recruiting to withdrawn prior to enrolment.
07 Jun 2021 Planned initiation date changed from 1 Jul 2021 to 1 Sep 2021.
02 Jun 2021 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com